[go: up one dir, main page]

DZ3442A1 - Combinaison de fenofibrate et de coenzyme q10 pour le traitement de dysfonctionnement endothelial - Google Patents

Combinaison de fenofibrate et de coenzyme q10 pour le traitement de dysfonctionnement endothelial

Info

Publication number
DZ3442A1
DZ3442A1 DZ013442A DZ013442A DZ3442A1 DZ 3442 A1 DZ3442 A1 DZ 3442A1 DZ 013442 A DZ013442 A DZ 013442A DZ 013442 A DZ013442 A DZ 013442A DZ 3442 A1 DZ3442 A1 DZ 3442A1
Authority
DZ
Algeria
Prior art keywords
fenofibrate
coenzyme
treatment
combination
endothelial dysfunction
Prior art date
Application number
DZ013442A
Other languages
English (en)
Inventor
Gerald Watts
David Playford
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR1038A external-priority patent/AUPR103800A0/en
Priority claimed from AUPR3424A external-priority patent/AUPR342401A0/en
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Application granted granted Critical
Publication of DZ3442A1 publication Critical patent/DZ3442A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DZ013442A 2000-10-26 2001-10-23 Combinaison de fenofibrate et de coenzyme q10 pour le traitement de dysfonctionnement endothelial DZ3442A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR1038A AUPR103800A0 (en) 2000-10-26 2000-10-26 Compositions for the treatment of endothelial dysfunction
AUPR3424A AUPR342401A0 (en) 2001-02-28 2001-02-28 Compositions for the treatment of endothelial dysfunction
PCT/EP2001/012425 WO2002034259A1 (fr) 2000-10-26 2001-10-23 Combinaison de fenofibrate et de coenzyme q10 permettant de traiter un dysfonctionnement endothelial

Publications (1)

Publication Number Publication Date
DZ3442A1 true DZ3442A1 (fr) 2002-05-02

Family

ID=25646491

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013442A DZ3442A1 (fr) 2000-10-26 2001-10-23 Combinaison de fenofibrate et de coenzyme q10 pour le traitement de dysfonctionnement endothelial

Country Status (29)

Country Link
US (1) US7410983B2 (fr)
EP (1) EP1328266B1 (fr)
JP (1) JP4236464B2 (fr)
KR (1) KR100862129B1 (fr)
CN (1) CN1220488C (fr)
AR (1) AR035071A1 (fr)
AT (1) ATE316787T1 (fr)
AU (1) AU2176502A (fr)
BG (1) BG65979B1 (fr)
BR (1) BR0114701A (fr)
CA (1) CA2426625C (fr)
CY (1) CY1105007T1 (fr)
CZ (1) CZ301282B6 (fr)
DE (1) DE60117046T2 (fr)
DK (1) DK1328266T3 (fr)
DZ (1) DZ3442A1 (fr)
EE (1) EE05281B1 (fr)
ES (1) ES2257457T3 (fr)
HU (1) HUP0303566A3 (fr)
IL (2) IL155524A0 (fr)
MA (1) MA25847A1 (fr)
MX (1) MXPA03003733A (fr)
NO (1) NO332260B1 (fr)
PL (1) PL212952B1 (fr)
PT (1) PT1328266E (fr)
RU (1) RU2003111175A (fr)
SK (1) SK287992B6 (fr)
TN (1) TNSN01151A1 (fr)
WO (1) WO2002034259A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360417T1 (de) 2001-07-11 2007-05-15 Boehringer Ingelheim Pharma Methode zur behandlung von zytokinvermittelten erkrankungen
US20060052457A1 (en) * 2002-03-11 2006-03-09 Peter Zahradka Use of ppar alpha agonists for the treatment of vascular and renal diseases
US20070225614A1 (en) * 2004-05-26 2007-09-27 Endothelix, Inc. Method and apparatus for determining vascular health conditions
FR2845602B1 (fr) * 2002-10-11 2005-07-08 Servier Lab Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
FR2868313B1 (fr) * 2004-03-31 2008-08-15 Servier Lab Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
EP1621200A1 (fr) * 2004-07-26 2006-02-01 Fournier Laboratories Ireland Limited Combinaison pharmaceutique comprenant un inhibiteur de l'aggregation des thrombocytes et un fibrate
CA2996149A1 (fr) 2005-06-01 2006-12-07 Bioelectron Technology Corporation Medicaments pouvant subir une oxydo-reduction destines au traitement des maladies mitochondriales et d'autres affections et modulation de biomarqueurs relatifs a l'etat energetique
ES2823728T3 (es) 2005-09-15 2021-05-10 Ptc Therapeutics Inc Variantes de cola de agentes terapéuticos con actividad redox para el tratamiento de enfermedades mitocondriales y otras afecciones y la modulación de biomarcadores de energía
EP1785133A1 (fr) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Utilisation du fenofibrate ou d'un de ses dérivés pour la prevention de la retinopathie diabetique
EP1986636B1 (fr) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Derives du phenol et de la 1,4-benzoquinone pour leur utilisation dans le traitement des maladies mitochondriales
WO2007106912A2 (fr) * 2006-03-16 2007-09-20 University Of Pittsburgh Of The Commonwealth System Of Higher Education Agonistes du récepteur-alpha activé de la prolifération des peroxysomes pour la conservation d'organe
US20070225606A1 (en) * 2006-03-22 2007-09-27 Endothelix, Inc. Method and apparatus for comprehensive assessment of vascular health
US20080027330A1 (en) * 2006-05-15 2008-01-31 Endothelix, Inc. Risk assessment method for acute cardiovascular events
US20080081963A1 (en) * 2006-09-29 2008-04-03 Endothelix, Inc. Methods and Apparatus for Profiling Cardiovascular Vulnerability to Mental Stress
KR100989093B1 (ko) 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
CA2736250C (fr) 2008-09-10 2016-12-20 Edison Pharmaceuticals, Inc. Traitement de troubles globaux du developpement grace a des agents therapeutiques a activite oxydo-reductrice
WO2010088378A1 (fr) * 2009-01-29 2010-08-05 Levine Joshua D Procédé d'ajout d'agents botaniques/de suppléments de régime à des agents pharmaceutiques dans un régime pharmacothérapeutique
US8973851B2 (en) * 2009-07-01 2015-03-10 The Procter & Gamble Company Apparatus and methods for producing charged fluid droplets
WO2011117429A1 (fr) * 2010-03-26 2011-09-29 Vivacell Biotechnology España, S.L Dérivés quinone de cannabinoïdes
RU2554500C2 (ru) * 2013-09-20 2015-06-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ лечения ишемического инсульта
EP3389646A1 (fr) 2015-12-17 2018-10-24 BioElectron Technology Corporation Dérivés fluoroalkyle, fluoroalcoxy, phénoxy, hétéroaryloxy, alcoxy, et amine 1,4-benzoquinone pour le traitement de troubles du stress oxydatif
US10881686B2 (en) 2017-10-27 2021-01-05 Zeta Biolongevity, Inc Compositions and methods for treating and preventing proteinuria and endothelial erosion
CN110907407B (zh) * 2019-12-03 2022-02-25 东北石油大学 一种基于spr的高灵敏度光子准晶体光纤折射率传感器

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229385A (en) * 1986-01-30 1993-07-20 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FI102273B1 (fi) 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyttö
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999027952A1 (fr) 1997-11-28 1999-06-10 Nikolai Vasilievich Karsanov Produit anti-hypoxique et anti-ischemique
WO2001015593A2 (fr) * 1999-09-02 2001-03-08 Drake Larson Compositions de reduction de formation de la plaque vasculaire et procedes d'utilisation associes

Also Published As

Publication number Publication date
CN1471390A (zh) 2004-01-28
PL361635A1 (en) 2004-10-04
SK287992B6 (sk) 2012-09-03
PL212952B1 (pl) 2012-12-31
BG107765A (bg) 2004-02-27
MA25847A1 (fr) 2003-07-01
PT1328266E (pt) 2006-05-31
DE60117046T2 (de) 2006-09-28
US20040022778A1 (en) 2004-02-05
CA2426625C (fr) 2010-06-01
SK5082003A3 (en) 2003-11-04
NO332260B1 (no) 2012-08-13
ES2257457T3 (es) 2006-08-01
CN1220488C (zh) 2005-09-28
EP1328266A1 (fr) 2003-07-23
DK1328266T3 (da) 2006-06-06
AU2176502A (en) 2002-05-06
AR035071A1 (es) 2004-04-14
BR0114701A (pt) 2003-11-18
BG65979B1 (bg) 2010-08-31
NO20031851L (no) 2003-06-24
US7410983B2 (en) 2008-08-12
JP2004512302A (ja) 2004-04-22
IL155524A0 (en) 2003-11-23
IL155524A (en) 2008-08-07
KR20030055276A (ko) 2003-07-02
WO2002034259A1 (fr) 2002-05-02
EE05281B1 (et) 2010-04-15
NO20031851D0 (no) 2003-04-24
TNSN01151A1 (en) 2005-11-10
EE200300165A (et) 2003-06-16
DE60117046D1 (de) 2006-04-13
CY1105007T1 (el) 2009-11-04
RU2003111175A (ru) 2004-09-10
KR100862129B1 (ko) 2008-10-09
CA2426625A1 (fr) 2002-05-02
CZ301282B6 (cs) 2009-12-30
HUP0303566A2 (hu) 2004-03-01
JP4236464B2 (ja) 2009-03-11
EP1328266B1 (fr) 2006-02-01
HK1057340A1 (en) 2004-04-02
ATE316787T1 (de) 2006-02-15
HUP0303566A3 (en) 2005-05-30
MXPA03003733A (es) 2004-10-15

Similar Documents

Publication Publication Date Title
DZ3442A1 (fr) Combinaison de fenofibrate et de coenzyme q10 pour le traitement de dysfonctionnement endothelial
MA25823A1 (fr) Compositions pour le traitement de l'eau.
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
EE200300239A (et) Rosuvastatiini (ZD4522) kasutamine heterosügootseperekondliku hüperkolesteroleemia raviks
AR027945A1 (es) Uso de pramipexol en el tratamiento de transtornos de adiccion
ITMI20001705A0 (it) Procedimento per la denitrificazione delle acque
DK1176964T3 (da) Brug af ET743 til behandling af cancer
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
DK1345598T3 (da) Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
NO20031525L (no) Kjemokinmutanter i behandlingen av multippel sklerose
NO20030978L (no) Behandling av urindysfunksjon
MA24569A1 (fr) Inhibiteurs de farnesyl-transferase en association avec des inhibiteurs de hmg-coa-reductase pour le traitement du cancer
PT1152756E (pt) Derivados de anticonvulsivo uteis no tratamento do autismo
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
DK1257278T3 (da) Anvendelse af mirtazapin til behandling af sövnforstyrrelser
EP1172113A4 (fr) Remedes pour le traitement des neuropathies automatiques
FR2808687B1 (fr) Medicament contenant des substances polysaccharidiques pour l'activation de l'apoptose
EP1572129A4 (fr) Derives d'amidine pour le traitement des amyloses
PT1273556E (pt) Estacao de tratamento simbiotico de aguas residuais.
FR2805983B3 (fr) Douche
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
FR2824752B1 (fr) Composition utilisable pour le conditionnement de boues